83-2271-59　［受注停止］KRIBIOLISA Sunitinib Malate （SUTENT） ELISA 1 x 96 wells　KOD1019

特徴

• Description：Enzyme Immunoassay for the quantitative determination of Sunitinib
• in serum, plasma and cell culture supernatant
• Sunitinib （SUTENT） is a medication used to treat cancer.
• It is a small-molecule, multi-targeted receptor
• tyrosine kinase （RTK） inhibitor that was approved by the FDA for the treatment of renal cell carcinoma （RCC）
• and imatinib-resistant gastrointestinal stromal tumor （GIST）.
• Sunitinib Malate is an antineoplastic agent, Flk-1
• inhibitor, and ATP-competitive inhibitor of PDGFRβ.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The KRIBIOLISA Sunitinib ELISA is a competitive inhibition immunoassay for the determination of Sunitinib.
• The microplate is coated with VEGFA protein.
• VEGFA protein is a known dimeric glycoprotein which functions as a
• ligand for the receptor VEGFR2 （Flk1）.
• Samples and standards containing Sunitinib is added to the plate with HRP
• conjugated VEGFR-2 from the kit simultaneously.
• The Sunitinib in the samples and standard will inhibit the binding
• of VEGFR-2 to the microplate.
• The amount of Sunitinib is inversely proportional to the color developed in the
• microplate post addition of TMB substrate and stopping the reaction.
• The absorbance is read at 450 nm.